Use of beta-blocker is associated with lower mortality in patients with coronary artery disease with or without COPD
Beta-blockers are recommended in the treatment of coronary artery disease (CAD) due to their efficacy in reducing disease-related morbidity and mortality. However, in patients with a co-diagnosis of chronic obstructive pulmonary disease (COPD), beta-blockers are less frequently prescribed due to concerns over their effect on patient lung function and fear of acute bronchospasms. Despite these fears, emerging evidence has shown that cardio-selective beta-blockers may have a beneficial effect in the treatment of patients with CAD and COPD. But there is little evidence available of the use of beta-blockers and their clinical impact in patients with CAD and COPD in Austria. The aim of this study was to investigate the epidemiological data on beta-blocker use in hospitalised CAD patients in Austria between 2006 and 2007. Using this data, researchers explored the association in beta-blocker use and overall mortality in patients with CAD and a co-diagnosis of COPD. Results demonstrated that of the 65,717 patients diagnosed with CAD, 46% were also diagnosed with COPD. Of this 46%, 77% were recorded users of beta-blockers. Analysis highlighted that 6.9% of these beta-blocker users diagnosed with COPD died within 6 months compared with 22.6% of non-users. In comparison, in patients diagnosed with CAD only, 5.4% of beta-blocker users and 23.1% of non-users died within 6 months. Researchers concluded that mortality of beta-blocker users was markedly lower than that of non-users in patients with or without COPD. Based on these findings, they recommended the use of these therapies in patients with CAD and a co-diagnosis of COPD to help improve patient outcomes.